In 2023, the market size of China's pharmaceutical intermediates may exceed 200 billion yuan! Key enterprise predictive analytics is coming

【Pharmaceutical Network Market Analysis】 Pharmaceutical intermediates industry is an important link in the pharmaceutical industry chain, with the industrial structure adjustment of large multinational pharmaceutical companies and the further refinement of the international division of labor, China has formed a complete pharmaceutical intermediates industrial system from scientific research and development to production and sales, and has become the world's major pharmaceutical intermediates export country, supply capacity continues to improve
。 Data show that in 2021, the market size of China's pharmaceutical intermediates increased by 4.
5% year-on-year, reaching 218.
4 billion yuan, and it is expected that in 2022, the market size of China's pharmaceutical intermediates will reach 227.
8 billion yuan, and by 2023, the market size may reach 237.
9 billion yuan
.
It is reported that at present, the representative pharmaceutical intermediates production companies in China include Senxuan Pharmaceutical, Tianyu Co.
, Ltd.
, Fuxiang Pharmaceutical, Lianhua Technology, etc
.
Senxuan Pharmaceutical According to the data, Senxuan Pharmaceutical is a chemical API manufacturer in the pharmaceutical manufacturing industry, and involves the production and sales of various API intermediates and pharmaceutical and chemical intermediates
.
The company mainly develops its business
through the sales model of direct sales.
Senxuan Pharmaceutical recently said in an institutional survey that in the first three quarters of 2022, the company's production and operation were stable, and both revenue and profit increased, of which operating income increased by 24% year-on-year, and net profit attributable to listed companies increased by 38.
27%
year-on-year 。 In the field of APIs, affected by the gradual resumption of production by downstream foreign customers after the epidemic, export revenue has achieved a significant increase; In the field of pharmaceutical intermediates, with the full normal production and operation of subsidiary Ningxia Senxuan, the revenue of fluorochlorine series pharmaceutical intermediates has increased significantly; In the field of oxygen-containing heterocyclic chemical intermediates, the increase in demand for dioxane products from downstream customers has also led to the growth
of overall revenue.
Senxuan Pharmaceutical said that the company has fully considered the future development in the project design stage, and the current production capacity can basically meet the company's recent development; The capacity utilization rate of APIs is about 50%, the capacity utilization rate of pharmaceutical intermediates is about 60%, and the capacity utilization rate of dioxane in oxygen-containing heterocyclic chemical intermediates is about 80%; The capacity utilization rate of dioxygen pentacyclic is about 50%, and the new production capacity of the product has not yet been released, and it will seek market space
in the high-end market of electronic grade in the future.
Tianyu Co.
, Ltd.
According to the data, Tianyu Co.
, Ltd.
belongs to a large domestic API enterprise, and is also one of the large-scale and complete varieties of sartan antihypertensive drug APIs and intermediates manufacturers, which mainly focus on sartan APIs and intermediate products, while covering antiviral, anti-asthma, anticoagulant APIs and intermediates, CDMO business
.
Some institutions said that the company's performance in the first three quarters of 2022 is under short-term pressure, but the API new products, CDMO and preparation businesses laid out in the early stage are expected to usher in harvests one after another, new businesses can be expected to take off, and performance is expected to resume rapid growth
。 It is expected that the company's operating income in 2022-2024 will be 28.
13, 31.
46 and 3.
554 billion yuan, a year-on-year increase of 10.
5%, 11.
8% and 13.
0%; Net profit attributable to owners was 0.
75, 1.
44 and 315 million yuan (204, 2.
89 and 421 million yuan before adjustment), an increase of -63.
3%, 91.
0% and 119.
4%
year-on-year.
Fuxiang Pharmaceutical Fuxiang Pharmaceutical is a pharmaceutical enterprise
specializing in chemical drug research and development, production, sales and service.
The company has core technology, is currently an important β-lactamase inhibitor API production base in the industry, and is also one of the main suppliers of
carbapenem drugs.
On August 27, Fuxiang Pharmaceutical disclosed the "2022 Semi-annual Report", the company achieved operating income of 831 million yuan in the first half of the year, a year-on-year increase of 7.
13%; The net profit attributable to shareholders of the listed company was 45.
3133 million yuan, down 70.
26%
from the same period last year.
Recently, Fuxiang Pharmaceutical said that the construction of the company's VC project is progressing in an orderly manner, and the production capacity will be gradually released, and the company will further reduce costs and improve the core competitiveness
of products through comprehensive energy utilization and circular economy.
The company's cooperation with Lingkai Pharmaceutical and Lingfu Pharmaceutical Research Institute is actively advancing
.
Lianhua Technology The main business of Lianhua Technology is three major sectors
: plant protection, medicine and functional chemicals.
According to the third quarter report of Lianhua Technology in 2022, the company's main revenue was 5.
902 billion yuan, a year-on-year increase of 24.
51%; net profit attributable to owners was RMB343 million, up 23.
43% year-on-year; Non-net profit was RMB384 million, up 55.
47% year-on-year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 2.
199 billion yuan, a year-on-year increase of 27.
38%; The net profit attributable to the parent in a single quarter was 138 million yuan, a year-on-year increase of 56.
03%; Quarterly non-net profit was RMB172 million, up 107.
74%
year-on-year.
Over the years, Lianhua Technology's pharmaceutical business has continued to extend to the front end, closely participated in the project development of customers from the early stage, and has been highly recognized by customers, and the revenue of pre-clinical phase III products has also increased
.
At the same time, based on the new needs of customers, the company builds a CRO platform, sets up a CRO team, and better provides customers with one-stop solutions, and the decoration of the company's CRO laboratory in Songjiang, Shanghai is almost completed
.
The company said that the verification of new pharmaceutical projects is progressing steadily according to plan, and if the project verification can be successfully completed, it can provide a guarantee
for the growth of the pharmaceutical business in the next few years.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.